News and Trends 28 Sep 2015
Sanofi and Regeneron’s Praluent succeeds at final hurdle with EU authorisation
Regeneron (NY, USA) has finally brought alirocumab (trade name Praluent) to the finish line with collaborator Sanofi, today announcing that the European commission has granted its hypercholesterolemia drug a marketing license for the EU. Having already been approved by the FDA in July, this completes Praluent’s launch into the Western pharma market. New-York based Regeneron […]
